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Abstract
Aims/hypothesis The finding that patients with diabetes due to
potassium channel mutations can transfer from insulin to sul-
fonylureas has revolutionised the management of patients
with permanent neonatal diabetes. The extent to which the
in vitro characteristics of the mutation can predict a successful
transfer is not known. Our aim was to identify factors associ-
ated with successful transfer from insulin to sulfonylureas in
patients with permanent neonatal diabetes due to mutations in
KCNJ11 (which encodes the inwardly rectifying potassium
channel Kir6.2).
Methods We retrospectively analysed clinical data on 127 pa-
tients with neonatal diabetes due to KCNJ11 mutations who
attempted to transfer to sulfonylureas. We considered transfer
successful when patients completely discontinued insulin
whilst on sulfonylureas. All unsuccessful transfers received
≥0.8 mg kg−1 day−1 glibenclamide (or the equivalent) for
>4 weeks. The in vitro response of mutant Kir6.2/SUR1 chan-
nels to tolbutamide was assessed in Xenopus oocytes. For
some specific mutations, not all individuals carrying the mu-
tation were able to transfer successfully; we therefore investi-
gated which clinical features could predict a successful
transfer.
Results In all, 112 out of 127 (88%) patients successfully
transferred to sulfonylureas from insulin with an improvement
in HbA1c from 8.2% (66 mmol/mol) on insulin, to 5.9%
(41 mmol/mol) on sulphonylureas (p=0.001). The in vitro
response of the mutation to tolbutamide determined the like-
lihood of transfer: the extent of tolbutamide block was <63%
for the p.C166Y, p.I296L, p.L164P or p.T293N mutations,
and no patients with these mutations successfully transferred.
However, most individuals with mutations for which tolbuta-
mide block was >73% did transfer successfully. The few pa-
tients with thesemutations who could not transfer had a longer
duration of diabetes than those who transferred successfully
(18.2 vs 3.4 years, p=0.032). There was no difference in pre-
transfer HbA1c (p=0.87), weight-for-age z scores (SD score;
p=0.12) or sex (p=0.17).
Conclusions/interpretation Transfer from insulin is success-
ful for most KCNJ11 patients and is best predicted by the
in vitro response of the specific mutation and the duration of
diabetes. Knowledge of the specific mutation and of diabetes
duration can help predict whether successful transfer to sulfo-
nylureas is likely. This result supports the early genetic testing
and early treatment of patients with neonatal diabetes aged
under 6 months.
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Introduction
Neonatal diabetes is a monogenic subtype of diabetes which
presents within the first 6 months of life [1]. A major cause of
neonatal diabetes is an activating mutation in the KCNJ11
gene, which encodes the inwardly rectifying potassium chan-
nel Kir6.2, which serves as the pore of the ATP-sensitive po-
tassium (KATP) channel. These mutations impair the ability of
the channel to close in response to metabolically generated
ATP, thereby preventing glucose-induced insulin secretion
from pancreatic beta cells. Prior to identification of the genetic
cause, neonatal diabetes patients with a KCNJ11 mutation
were treated with insulin. Subsequently, most have now trans-
ferred to sulfonylurea drugs, which directly close KATP chan-
nels and facilitate insulin release in response to food. This
results in improved glycaemic control, fewer hypoglycaemic
events and a simpler medication regime [2, 3].
A minority of individuals, however, are unable to fully stop
insulin treatment [2]. A recent study of 58 patients suggested
that the duration of diabetes prior to transfer correlated with
the maintenance dose of sulfonylurea after transfer [4]. Other
studies have suggested that the extent to which mutant chan-
nels are blocked by sulfonylureas in vitro predicts whether
transfer is possible [5]. Thus, the aim of this study was to
explore the effects of a wide range of KCNJ11 mutations,
and of diabetes duration, in a large sample (n=127) of patients
who attempted to transfer to sulfonylureas from insulin.
Methods
Patients We retrospectively analysed clinical data on 127 pa-
tients from across the world (electronic supplementary material
[ESM] Table 1) with mutations in the KCNJ11 gene, as se-
quenced by the Molecular Genetics Laboratory, University of
Exeter Medical School, UK. Data were collated from patients’
clinical records. For each patient, we noted the specific KCNJ11
mutation, date of birth, sex, date of diagnosis, date of initiation of
sulfonylurea, insulin dose (if applicable), sulfonylurea dose and
HbA1c level before and 4–12 months after sulfonylurea initia-
tion. Weight before or within a year of transfer was converted to
weight-for-age z scores (weight SD score) [6].
Transfer to sulfonylureas Patients with KCNJ11 mutation
and neonatal diabetes were transferred to sulfonylureas under
the supervision of their local clinicians, using the Exeter pro-
tocol [7]. We defined successful transfer as a patient who
could stop taking insulin altogether [2]. Unsuccessful transfer
was defined as a patient who remained on insulin, either alone
or in combination with a sulfonylurea, having attempted a
dose of at least 0.8 mg/kg/day glibenclamide for at least
4 weeks (or the equivalent) [2].When patients were prescribed
a different sulfonylurea, the dose was calculated as a percent-
age of the maximum dose (according to the British National
Formulary [www.bnf.org/]) and converted to an equivalent
dose of glibenclamide, as described elsewhere [2]. All
patients were treated with insulin before genetic diagnosis.
None of the patients, including those unable to transfer, was
prescribed any medication other than insulin and/or sulfonyl-
ureas to treat their diabetes.
Functional analysis The sulfonylurea sensitivity of recombi-
nant wild-type and mutant pancreatic beta cell KATP channels
(composed of Kir6.2 and sulphonylurea receptor 1 [SUR1]
subunits) was measured in vitro using tolbutamide, as previ-
ously described [2]. Briefly, channels were expressed in
Xenopus oocytes and whole-cell currents recorded by a two-
electrode voltage clamp. The heterozygous state was simulat-
ed by co-injecting ABCC8 mRNA (encoding SUR1) with
50:50 wild-type and mutant KCNJ11 mRNA. Currents were
activated by metabolic inhibition by azide (3 mmol/l) and the
percentage block in response to tolbutamide (0.5 mmol/l; a
maximally effective dose for wild-type channels) was
measured.
Statistical analysis Clinical data were analysed using the
Mann–Whitney U test and expressed as the median and inter-
quartile range. Analysis was performed using Stata version
13.1 (StataCorp, College Station, Texas, USA).
Ethics statement This study was not deemed to require re-
search ethics committee approval under Governance
Arrangements for Research Ethics Committees guidelines be-
cause it involved research undertaken by staff within a care
team using information collected in the course of care of their
patients, which was anonymised for this study.
Results
Most patients with diabetes due to aKCNJ11mutation can
transfer to sulfonylureas with improved glycaemic control
A total of 127 patients attempted transfer to sulfonylureas, and
reached a dose of at least 0.8 mg/kg/day glibenclamide or an
equivalent dose of another sulfonylurea. Of these, 112 (88%)
transferred successfully and achieved excellent glycaemic
control with sulfonylureas alone. In all, 15 patients failed to
respond and remained on either insulin alone or insulin com-
bined with a sulfonylurea. In patients who successfully trans-
ferred the median HbA1c level fell from 8.2% (66 mmol/mol)
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on insulin to 5.9% (41 mmol/mol) after 4–12 months on
sulphonylureas (p=0.001).
In vitro and in vivo sulfonylurea responses are strongly
affected by the specific KCNJ11 mutation Figure 1 shows
the extent of in vitro sulfonylurea block of wild-type channels
and a range of mutant KATP channels vs the number of patients
with each mutation who did or did not successfully transfer to
sulfonylurea therapy. There is a clear correlation between the
extent of block and the ability to transfer. No patients with the
p.C166Y, p.I296L, p.L164P or p.T293N mutations (associat-
ed with a tolbutamide block of <63%) transferred. In contrast,
most individuals with mutations associated with a tolbutamide
block of >73% were able to transfer.
A shorter diabetes duration is associated with successful
transfer to insulin independence For six KCNJ11 mutations
(p.R201H, p.R201C, p.V59M, p.G334C, p.G53S and p.Q52R),
some patients transferred to sulfonylureas whereas others did not
(Fig. 1, grey bars). Those who successfully transferred had a
shorter duration of diabetes prior to transfer compared with those
who did not (mean 3.4 years [interquartile range (IQR) 0.3–11.9]
vs 18.2 years [IQR 16.2, 18.9]; p=0.032; Fig. 2).
Multivariate analysis showed that duration of diabetes (OR
0.92 [95%CI 0.86, 0.98], p=0.008) and percentage tolbutamide
block (OR 1.2 [95% CI 1.1, 1.3], p<0.001) were independent
and additive predictors of successful transfer to sulfonylureas.
The transfer success rate in patients with KCNJ11 muta-
tions was not associated with sex (p=0.17), weight SD score
at the time of transfer (p=0.12) or the median HbA1c level
prior to attempted transfer (p=0.87; ESM Table 2).
Discussion
Most patients (88%) with neonatal diabetes due to a KCNJ11
mutation could switch from insulin to sulfonylurea therapy and
achieve near-normal glycaemia (HbA1c 5.9% [41 mmol/mol]).
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Fig. 1 Sulfonylurea block of wild-type and mutant KATP channels.
Percentage inhibition of whole-cell KATP channel currents in wild-type
(WT) and mutant (as indicated) channels in response to 0.5 mmol/l tol-
butamide. Current in the presence of tolbutamide is expressed as a per-
centage of that in the absence of drug [2, 9, 11–14]. The numbers in
parenthesis indicate the number of patients who responded to
sulfonylureas (left) out of the total number (right) with the indicated
mutation. White bars, all patients responded; grey bars, some patients
responded; black bars, no patients responded. The vertical light grey bar
indicates the level of block that separates those patients who responded
from those who did not
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Fig. 2 The younger the patients are (i.e. the shorter the duration of dia-
betes), the greater the likelihood of a successful transfer. Only KCNJ11
mutations for which some patients transfer and others do not (p.R201H,
p.R201C, p.V59M, p.G334C, p.G53S, p.Q52R) are shown. White bars,
successful transfer; black bars, unsuccessful transfer
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However, our data show that successful transfer was influenced
by both the specific mutation and the duration of diabetes.
All patients with the p.L164P, p.C166Y, p.T293N and
p.I296L mutations failed to transfer to sulfonylurea therapy.
This may be explained by the greatly reduced ability of sulfo-
nylureas to block the mutant KATP channels. Sulfonylureas
produce KATP channel inhibition by stabilising the long closed
state of the channel [8]. The p.L164P, p.C166Y, p.T293N and
p.I296L mutations dramatically decrease the time that the
channel spends in this state, and thereby greatly reduce sulfo-
nylurea inhibition [5, 9]. It is therefore very unlikely that pa-
tients with these mutations could transfer to sulfonylureas
even if the dose were greatly increased. Therefore, a KATP
channel blocker with a different mechanism of action is
required.
For most mutations, all patients could transfer to sulfonyl-
ureas (Fig. 1, white bars; ESM Table 3). However, in each
patient group, the numbers involved were relatively small.
Thus, it is possible that later studies may identify some indi-
viduals with these mutations who fail to transfer. However,
this will not be a consequence of a failure of sulfonylureas to
block the KATP channel.
Of special interest are those mutations for which some pa-
tients transferred and others failed to do so despite taking an
adequate dose of sulfonylureas. These include the most com-
mon mutations (p.R201H, p.R201C and p.V59M). Among
these individuals, those who commenced sulfonylureas in
the 5 years after diabetes diagnosis were very likely to suc-
cessfully transfer. Recent recognition that diabetes before age
6 months is neonatal diabetes [1] and the availability of rapid
molecular genetic diagnosis means that almost all patients
should now be diagnosed withKCNJ11 diabetes within weeks
of diagnosis, thus facilitating a very early transfer.
One possible explanation for the better outcome when sulfo-
nylureas are commenced at an earlier stage is that the patient’s
beta cells have been exposed to chronic hyperglycaemia for a
shorter period. In an inducible mouse model of neonatal diabetes
carrying the KCNJ11 p.V59Mmutation, animals that were treat-
ed with glibenclamide shortly after gene induction showed nor-
mal islet cell morphology and excellent glycaemic control [10].
In contrast, mice exposed to chronic hyperglycaemia exhibited
marked changes in insulin content and islet structure: these mice
either required substantially more sulfonylurea to achieve
normoglycaemia or sulfonylurea therapy was ineffective. This
suggests that early initiation of sulfonylureas, and thus less ex-
posure of beta cells to hyperglycaemia/hypoinsulinaemia, is im-
portant for successful transfer. In addition, it is possible that
developmental changes influence beta cell function and that
these are adversely affected by KATP channel overactivity or
hyperglycaemia/hypoinsulinaemia.
In six individuals, the insulin dose was reduced by >50%
but could not be discontinued completely. In these patients,
we strongly support continuing both sulfonylurea and insulin.
However, if there is no measurable C-peptide and no change
in insulin dose when sulfonylurea treatment is used, then the
only reason to continue sulfonylurea therapy is if beneficial
effects on central nervous system function are observed. If this
is not seen after a trial of at least 3 months, then sulfonylureas
can be discontinued.
This study shows that the specificKCNJ11mutation and its
in vitro response to tolbutamide is a crucial determinant of
whether a patient will be able to transfer to sulfonylureas from
insulin. For patients with responsive mutations, sulfonylurea
transfer is less likely to succeed when it is attempted decades
after diabetes diagnosis. This result emphasises the impor-
tance of obtaining an early molecular genetic diagnosis of
KCNJ11 neonatal diabetes because this provides information
on whether transfer from insulin is likely to be successful and
enables its rapid implementation.
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